[{"address1": "50 Broadway", "address2": "7th Floor", "city": "London", "zip": "SW1H 0DB", "country": "United Kingdom", "phone": "44 20 7400 3347", "website": "https://roivant.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.", "fullTimeEmployees": 904, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew  Gline", "age": 39, "title": "CEO & Director", "yearBorn": 1984, "fiscalYear": 2022, "totalPay": 1772089, "exercisedValue": 0, "unexercisedValue": 1863054}, {"maxAge": 1, "name": "Dr. Eric  Venker M.D., Pharm.D.", "age": 36, "title": "President & COO", "yearBorn": 1987, "fiscalYear": 2022, "totalPay": 1281230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mayukh  Sukhatme M.D.", "age": 47, "title": "President, Chief Investment Officer & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 1718846, "exercisedValue": 0, "unexercisedValue": 2026930}, {"maxAge": 1, "name": "Mr. Richard  Pulik", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rakhi  Kumar", "age": 43, "title": "Chief Accounting Officer", "yearBorn": 1980, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Huafeng  Xu Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jo  Chen", "title": "General Counsel", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Graff", "title": "Head of People", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne L. Romeo", "age": 55, "title": "Head of Global Transactions & Risk Management", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Gasner", "title": "Executive Vice President of Roivant Health", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.9, "open": 10.78, "dayLow": 10.514, "dayHigh": 10.91, "regularMarketPreviousClose": 10.9, "regularMarketOpen": 10.78, "regularMarketDayLow": 10.514, "regularMarketDayHigh": 10.91, "beta": 1.342, "trailingPE": 2.064516, "forwardPE": -8.180451, "volume": 3719575, "regularMarketVolume": 3719575, "averageVolume": 7456567, "averageVolume10days": 4510660, "averageDailyVolume10Day": 4510660, "bid": 10.87, "ask": 10.9, "bidSize": 3800, "askSize": 1900, "marketCap": 8767604736, "fiftyTwoWeekLow": 8.06, "fiftyTwoWeekHigh": 13.24, "priceToSalesTrailing12Months": 71.141945, "fiftyDayAverage": 10.9448, "twoHundredDayAverage": 10.64275, "currency": "USD", "enterpriseValue": 3098192640, "profitMargins": 36.24138, "floatShares": 421642806, "sharesOutstanding": 805846016, "sharesShort": 45129442, "sharesShortPriorMonth": 31571151, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.055999998, "heldPercentInsiders": 0.20622998, "heldPercentInstitutions": 0.62175, "shortRatio": 4.05, "shortPercentOfFloat": 0.105, "impliedSharesOutstanding": 807326976, "bookValue": 7.566, "priceToBook": 1.4380121, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": 4351862784, "trailingEps": 5.27, "forwardEps": -1.33, "enterpriseToRevenue": 25.139, "enterpriseToEbitda": -3.022, "52WeekChange": 0.27251458, "SandP52WeekChange": 0.21080327, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ROIV", "underlyingSymbol": "ROIV", "shortName": "Roivant Sciences Ltd.", "longName": "Roivant Sciences Ltd.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9d037e9b-5cb8-3bad-8efe-5f0e5f374cbd", "messageBoardId": "finmb_282015801", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.88, "targetHighPrice": 20.0, "targetLowPrice": 12.0, "targetMeanPrice": 15.9, "targetMedianPrice": 16.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 6670810112, "totalCashPerShare": 8.278, "ebitda": -1025345984, "totalDebt": 506579008, "quickRatio": 27.497, "currentRatio": 27.794, "totalRevenue": 123241000, "debtToEquity": 7.693, "revenuePerShare": 0.16, "returnOnAssets": -0.13768, "returnOnEquity": 1.05802, "freeCashflow": -502471008, "operatingCashflow": -835899008, "revenueGrowth": 1.178, "operatingMargins": -7.74171, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]